Nanoparticulate systems for the delivery of antisense oligonucleotides

被引:152
作者
Lambert, G [1 ]
Fattal, E [1 ]
Couvreur, P [1 ]
机构
[1] Fac Pharm Chatenay Malabry, URA CNRS 8612, Lab Phys Chim Pharmacotech & Biopharm, F-92296 Chatenay Malabry, France
关键词
nanoparticles; nanocapsules; nanospheres; oligonucleotide; antisense;
D O I
10.1016/S0169-409X(00)00116-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Antisense oligonucleotides are molecules that are able to inhibit gene expression being therefore potentially active for the treatment of viral infections or cancer, However, because of their poor stability in biological medium and their weak intracellular penetration, colloidal drugs carriers such as nanoparticles were developed for the delivery of oligonucleotides (ODN). ODN associated to nanoparticles were shown to be protected against degradation and to penetrate more easily into different types of cells. As a consequence, nanoparticles were shown to improve the efficiency of ODNs for the inhibition of the proliferation of cells expressing the point mutated Ha-ras gene. In vivo, polyalkylcyanoacrylate (PACA) nanoparticles were able to efficiently distribute the ODNs to the liver whereas the alginate nanosponges could concentrate the ODNs in the lungs. Finally, ODN loaded to PACA nanoparticles were able to improve in mice, the treatment of RAS cells expressing the point mutated Ha-ras gene, (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:99 / 112
页数:14
相关论文
共 50 条
[41]   The use of antisense oligonucleotides in Xenopus oocytes [J].
Hulstrand, Alissa M. ;
Schneider, Patricia N. ;
Houston, Douglas W. .
METHODS, 2010, 51 (01) :75-81
[42]   Antisense oligonucleotides for cancer therapy - an overview [J].
Stahel, RA ;
Zangemeister-Wittke, U .
LUNG CANCER, 2003, 41 :S81-S88
[43]   Targeting Kupffer cells with antisense oligonucleotides [J].
Ponnappa, BC ;
Israel, Y .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2002, 7 :E223-E233
[44]   Applying antisense technology -: Affinitak™ and other antisense oligonucleotides in clinical development [J].
Holmlund, JT .
THERAPEUTIC OLIGONUCLEOTIDES: ANTISENSE, RNAI, TRIPLE-HELIX, GENE REPAIR, ENHANCER DECOYS, CPG AND DNA CHIPS, 2003, 1002 :244-251
[45]   Microparticulate and nanoparticulate drug delivery systems for metformin hydrochloride [J].
Cetin, Meltem ;
Sahin, Selma .
DRUG DELIVERY, 2016, 23 (08) :2796-2805
[46]   The influence of nanoparticulate drug delivery systems in drug therapy [J].
Aminu, Nafiu ;
Bello, Idris ;
Umar, Nura Muhammad ;
Tanko, Nuhu ;
Aminu, Abdulmalik ;
Audu, Momoh Mumuni .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2020, 60
[47]   Local delivery of c-myb antisense oligonucleotides during balloon angioplasty [J].
Azrin, MA ;
Mitchel, JF ;
Bow, LM ;
Pedersen, CA ;
Cartun, RW ;
Aretz, TH ;
Waters, DD ;
McKay, RG .
CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1997, 41 (03) :232-240
[48]   Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides [J].
Juliano, R. L. ;
Carver, K. ;
Cao, C. ;
Ming, X. .
JOURNAL OF DRUG TARGETING, 2013, 21 (01) :27-43
[49]   Towards genomic drug therapy with antisense oligonucleotides [J].
Lonnberg, H ;
Vuorio, E .
ANNALS OF MEDICINE, 1996, 28 (06) :511-522
[50]   Prerequisites for the use of antisense oligonucleotides in nuclear medicine [J].
Hildebrandt, M ;
Reske, SN .
NUKLEARMEDIZIN, 1996, 35 (04) :126-131